International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(6), С. 5220 - 5220
Опубликована: Март 9, 2023
In
recent
years,
Cannabis
use/misuse
for
treating
pregnancy-related
symptoms
and
other
chronic
conditions
has
increased
among
pregnant
women,
favored
by
decriminalization
and/or
legalization
of
its
recreational
uses
in
addition
to
easy
accessibility.
However,
there
is
evidence
that
prenatal
exposure
might
have
adverse
consequences
on
pregnancy
progression
a
deleterious
impact
proper
neurodevelopmental
trajectories
the
offspring.
Maternal
use
could
interfere
with
complex
finely
controlled
role
performed
endocannabinoid
system
reproductive
physiology,
impairing
multiple
gestational
processes
from
blastocyst
implantation
parturition,
long-lasting
intergenerational
effects.
this
review,
we
discuss
current
clinical
preclinical
regarding
endocannabinoids
development,
function,
immunity
maternal–fetal
interface,
focusing
constituents
each
these
processes.
We
also
intrinsic
limitations
available
studies
future
perspectives
challenging
research
field.
JAMA Network Open,
Год журнала:
2023,
Номер
6(5), С. e2312522 - e2312522
Опубликована: Май 9, 2023
Importance
The
use
of
cannabis
as
a
medicine
is
becoming
increasingly
prevalent.
Given
the
diverse
range
conditions
being
treated
with
medical
cannabis,
well
vast
array
products
and
dose
forms
available,
clinical
evidence
incorporating
patient-reported
outcomes
may
help
determine
safety
efficacy.
Objective
To
assess
whether
patients
using
report
improvements
in
health-related
quality
life
over
time.
Design,
Setting,
Participants
This
retrospective
case
series
study
was
conducted
at
network
specialist
clinics
(Emerald
Clinics)
located
across
Australia.
were
who
received
treatment
for
any
indication
point
between
December
2018
May
2022.
Patients
followed
up
every
mean
(SD)
44.6
(30.1)
days.
Data
to
15
follow-ups
reported.
Statistical
analysis
from
August
September
Exposure
Medical
cannabis.
Product
types
cannabinoid
content
varied
time
accordance
treating
physician’s
judgement.
Main
Outcomes
Measures
main
outcome
measure
assessed
36-Item
Short
Form
Health
Survey
(SF-36)
questionnaire.
Results
In
this
3148
patients,
1688
(53.6%)
female;
820
(30.2%)
employed;
age
55.9
(18.7)
years
baseline
before
treatment.
Chronic
noncancer
pain
most
common
(68.6%
[2160
3148]),
by
cancer
(6.0%
[190
insomnia
(4.8%
[152
anxiety
(4.2%
[132
3148]).
After
commencing
reported
significant
relative
on
all
8
domains
SF-36,
these
mostly
sustained
controlling
potential
confounders
regression
model,
associated
an
improvement
6.60
(95%
CI,
4.57-8.63)
points
18.31
15.86-20.77)
SF-36
scores,
depending
domain
(all
P
<
.001).
Effect
sizes
(Cohen
d
)
ranged
0.21
0.72.
A
total
2919
adverse
events
reported,
including
2
that
considered
serious.
Conclusions
Relevance
study,
life,
which
Adverse
rarely
serious
but
common,
highlighting
need
caution
prescribing
Drug and Alcohol Dependence,
Год журнала:
2024,
Номер
257, С. 111263 - 111263
Опубликована: Март 8, 2024
The
prevalence
of
cannabis
use
disorders
(CUDs)
in
people
who
recreationally
has
been
estimated
at
22%,
yet
there
is
a
dearth
literature
exploring
CUDs
among
medicinal
cannabis.
We
aimed
to
systematically
review
the
In
our
systematic
and
meta-analysis,
we
followed
PRISMA
guidelines
searched
three
databases
(PsychInfo,
Embase
PubMed)
identify
studies
examining
Metaanalyses
were
calculated
on
CUDs.
Prevalence
estimates
pooled
across
different
periods
(recent
6-12
months)
using
DSM-IV
DSM-5.
conducted
14
eligible
publications,
assessing
with
diagnostic
criteria,
providing
data
for
3681
participants
from
five
countries.
demonstrated
that
demographic
factors,
mental
health
problems
management
chronic
pain
associated
an
elevated
risk
A
meta-analyses
was
For
individuals
past
months,
29%
(95%
CI:
21-38%)
as
per
DSM-5
criteria.
Similar
observed
(24%,
14-38%)
same
period.
substantial
comparable
recreational
reasons,
emphasizing
need
ongoing
research
monitor
Journal of Psychoactive Drugs,
Год журнала:
2025,
Номер
unknown, С. 1 - 10
Опубликована: Янв. 7, 2025
This
mixed-methods
study
investigated
the
role
of
medicinal
cannabis
use
among
younger
adults
who
live
in
rural
communities
and
experience
high
levels
cumulative
social
disadvantage
(CSD).
Results
are
based
on
cross-sectional
surveys
online
interviews
with
153
(18-35-years
old)
California.
We
assessed
participants'
CSD
(high,
medium,
low)
examined
associations
perceived
general
physical
mental
health
(MUC).
Qualitative
analyses
were
then
conducted
to
better
understand
roles
lives
participants
versus
low
CSD.
High
was
associated
poorer
MUC,
but
not
past
month
use.
findings
emphasized
significant
MUC
for
young
people
reduce
stress
manage
health.
Findings
suggest
need
address
inequities
communities,
such
as
increasing
access
care,
reliance
managing
Journal of Psychoactive Drugs,
Год журнала:
2025,
Номер
unknown, С. 1 - 10
Опубликована: Фев. 7, 2025
The
study
aims
to
assess
cannabis
dependency
among
individuals
who
cultivate
for
medical
and/or
recreational
purposes.
Participants
included
growers
cultivated
personal
use,
social
supply,
caregiving
activities,
or
illegal
sales.
Between
December
2020
and
August
2021,
we
conducted
an
online
cross-sectional
survey
Georgian
growers.
We
used
the
International
Cannabis
Cultivation
Questionnaire
measure
purpose
of
growing
Severity
Dependence
Scale
(SDS).
Logistic
regression
analysis
was
factors
associated
with
dependency.
Out
218
growers,
193
(88.5%)
grew
their
use.
Among
participants,
132
(68%)
61
(32%)
it
overall
prevalence
use
37.7%.
In
multiple
logistic
analysis,
users
(AOR
0.39,
P-value
<
.05)
had
lower
odds
developing
compared
users.
Growers
purposes
were
more
likely
consume
on
a
daily
almost
basis.
majority
(illegal)
products
consumption,
mostly
This
group
higher
odd
those
Pharmaceutics,
Год журнала:
2025,
Номер
17(3), С. 319 - 319
Опубликована: Март 1, 2025
Cannabis
is
the
most
commonly
used
illicit
substance
worldwide.
Recent
years
have
seen
an
increase
in
cannabis
consumption,
and
with
new
approvals
therapeutic
indications,
there
are
challenges
minimizing
risks
interactions
between
cannabis-based
products,
prescription
drugs,
other
approved
substances
of
abuse.
Thus,
identifying
enzymes
metabolizing
cannabinoid
drugs
their
relationship
crucial
for
understanding
potential
effects
simultaneous
use.
This
article
offers
a
comprehensive
review
pharmacokinetic
as
well
It
also
compiles
existing
evidence
these
describes
clinical
outcomes
associated
inhibition
or
induction
various
enzymes.
Frontiers in Neurology,
Год журнала:
2022,
Номер
13
Опубликована: Май 30, 2022
Background
Medical
cannabis
(MC)
has
been
hypothesized
as
an
alternative
therapy
for
migraines,
given
the
undesirable
side
effects
of
current
migraine
medications.
The
objective
this
review
was
to
assess
effectiveness
and
safety
MC
in
treatment
adults.
Methods
We
searched
PubMed,
EMBASE,
PsycINFO,
CINAHL,
Web
Science
eligible
studies
adults
aged
18
years
older.
Two
reviewers
independently
screened
eligibility.
A
narrative
synthesis
included
conducted.
Results
total
12
publications
involving
1,980
participants
Italy
United
States
America
were
included.
significantly
reduced
nausea
vomiting
associated
with
attacks
after
6
months
use.
Also,
number
days
30
days,
frequency
headaches
per
month.
51%
more
effective
reducing
migraines
than
non-cannabis
products.
Compared
amitriptyline,
aborted
some
(11.6%)
users
frequency.
While
use
occurrence
medication
overuse
(MOH),
adverse
events
mostly
mild
occurred
43.75%
patients
who
used
oral
cannabinoid
preparations.
Conclusions
There
is
promising
evidence
that
may
have
a
beneficial
effect
on
onset
duration
However,
well-designed
experimental
MC's
treating
are
needed
support
hypothesis.
Nutrition in Clinical Practice,
Год журнала:
2024,
Номер
39(4), С. 815 - 823
Опубликована: Март 30, 2024
The
endocannabinoid
system
(ECs)
is
composed
of
multiple
signaling
compounds
and
receptors
within
the
central
peripheral
nervous
along
with
various
organs,
including
gut,
liver,
skeletal
muscle.
ECs
has
been
implicated
in
metabolism,
gut
motility,
eating
behaviors.
altered
disease
states
such
as
obesity.
Recent
studies
have
clarified
role
microbiome
nutrition
on
ECs.
Exogenous
cannabinoid
(CB)
use,
either
organic
or
synthetic,
stimulates
through
CB1
CB2
receptors.
However,
CBs
unclear
regard
to
optimization
treat
states.
This
review
briefly
summarizes
effect
exogenous
metabolism
nutrition.
With
increased
legalization
cannabis,
there
a
corresponding
use
United
States.
Therefore,
clinicians
need
be
aware
both
benefits
harm
cannabis
overall
status,
well
gaps
knowledge
for
future
research
guideline
development.
Pharmacopsychiatry,
Год журнала:
2024,
Номер
57(03), С. 141 - 151
Опубликована: Март 11, 2024
Abstract
Introduction
Perceptions
of
cannabis
as
a
potential
medical
treatment
for
mood
and
anxiety
disorders
have
been
increasing
in
the
context
legalizations,
availability,
programs,
though
current
evidence
predominately
indicates
risks
negative
effects
use
(CU)
on
mental
health
outcomes.
This
study
aims
to
understand
motivations,
perceptions,
effects,
patterns
CU
individuals
with
disorders.
Methods
Thirty-six
adult
patients
diagnosed
or
disorders,
obsessive-compulsive
disorder,
posttraumatic
stress
disorder
who
were
currently
using
completed
an
in-depth
qualitative
interview
individual
experiences,
their
CU.
The
thematic
analysis
focused
phases
sources
products
information.
Results
Reported
motivations
initiation
included
curiosity,
peer
pressure,
dissatisfaction
conventional
treatments.
Factors
such
psychotropic
coping
symptoms
insomnia
contributed
continuation
More
including
cognitive
dysfunction,
worsening
mood,
symptoms,
acknowledged
ongoing
Concerning
findings
common
before
age
18,
combined
recreational
CU,
rare
consultation
professionals
harms.
Discussion
Findings
indicate
complexity
population.
reported
beneficial
specific
should
be
further
investigated.
emphasize
patient-provider
dialogue
both
Information
from
this
can
contribute
inform
development
education,
prevention,
intervention
strategies.
Abstract
One-fifth
of
US
adults
experience
chronic
pain,
which
is
associated
with
increased
tobacco
and
cannabis
use.
Although
bidirectional
relationships
between
pain
have
been
demonstrated,
pathways
use,
co-use
are
understudied.
We
aimed
to
estimate
the
effects
(1)
substance
use
(exclusive
tobacco)
on
later
intensity,
(2)
intensity
Data
were
from
31,983
in
biennial
surveys
(2015-2021)
nationally
representative
longitudinal
Population
Assessment
Tobacco
Health
Study
(n
=
71,055
pairs
consecutive
surveys;
T1
T2).
Past-week
was
dichotomized
(≤4/10
no/low
pain;
>4/10
moderate/severe
pain).
Mutually
exclusive
categories
(past
30
days)
no
cannabis/tobacco
use;
co-use.
Logistic
regression
assessed
whether
affected
at
T2.
Multinomial
models
status
Compared
T1,
(OR:
2.29
[95%
CI:
2.09-2.51]),
(2.00
[1.86-2.14]),
(1.35
[1.13-1.61])
all
Moderate/severe
odds
(2.43
[2.22-2.66]),
(2.12
[1.98-2.28]),
(1.46
[1.29-1.65])
compared
T2,
T2
Findings
demonstrated
indicate
potential
synergy
respect
pain.